Tositumomab: Difference between revisions
Content deleted Content added
Anypodetos (talk | contribs) Added mab_type, updated source |
m Tag uncat using AWB |
||
| Line 1: | Line 1: | ||
{{drugbox |
{{drugbox |
||
| type = mab |
| type = mab |
||
| image = |
| image = |
||
| mab_type = mab |
| mab_type = mab |
||
| source = o |
| source = o |
||
| Line 7: | Line 7: | ||
| CAS_number = 192391-48-3 |
| CAS_number = 192391-48-3 |
||
| ATC_prefix = V10 |
| ATC_prefix = V10 |
||
| ATC_suffix = XA53 |
| ATC_suffix = XA53 |
||
| ATC_supplemental = (sequential regimen with <sup>131</sup>I form) |
| ATC_supplemental = (sequential regimen with <sup>131</sup>I form) |
||
| PubChem = |
| PubChem = |
||
| DrugBank = BTD00085 |
| DrugBank = BTD00085 |
||
| C=6416 | H=9874 | N=1688 | O=1987 | S=44 |
| C=6416 | H=9874 | N=1688 | O=1987 | S=44 |
||
| molecular_weight = 143859.7 g/mol |
| molecular_weight = 143859.7 g/mol |
||
| bioavailability = |
| bioavailability = |
||
| protein_bound = |
| protein_bound = |
||
| metabolism = |
| metabolism = |
||
| elimination_half-life = |
| elimination_half-life = |
||
| excretion = |
| excretion = |
||
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
||
| pregnancy_US = <!-- A / B / C / D / X --> |
| pregnancy_US = <!-- A / B / C / D / X --> |
||
| pregnancy_category = |
| pregnancy_category = |
||
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 --> |
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 --> |
||
| legal_UK = <!-- GSL / P / POM / CD --> |
| legal_UK = <!-- GSL / P / POM / CD --> |
||
| legal_US = <!-- OTC / Rx-only --> |
| legal_US = <!-- OTC / Rx-only --> |
||
| legal_status = |
| legal_status = |
||
| routes_of_administration = |
| routes_of_administration = |
||
}} |
}} |
||
'''Tositumomab''' is a drug for the treatment of [[follicular lymphoma]]. It is a [[IgG]]2a anti-[[CD20]] [[monoclonal antibody]] derived from immortalized mouse cells. |
'''Tositumomab''' is a drug for the treatment of [[follicular lymphoma]]. It is a [[IgG]]2a anti-[[CD20]] [[monoclonal antibody]] derived from immortalized mouse cells. |
||
| Line 35: | Line 35: | ||
This drug combination is manufactured by [[Corixa]] (now [[GlaxoSmithKline]]). It sells in the U.S. under the trade name '''Bexxar'''. |
This drug combination is manufactured by [[Corixa]] (now [[GlaxoSmithKline]]). It sells in the U.S. under the trade name '''Bexxar'''. |
||
There is some evidence that it may cause a smaller decrease in [[platelet]] counts than [[ibritumomab tiuxetan]] does.<ref name="pmid17942813">{{ |
There is some evidence that it may cause a smaller decrease in [[platelet]] counts than [[ibritumomab tiuxetan]] does.<ref name="pmid17942813">{{Cite journal|author=Jacene HA, Filice R, Kasecamp W, Wahl RL |title=Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice |journal=[[J. Nucl. Med.]] |volume=48 |issue=11 |pages=1767–76 |year=2007 |pmid=17942813 |doi=10.2967/jnumed.107.043489 |url=http://jnm.snmjournals.org/cgi/pmidlookup?view=long&pmid=17942813}}</ref> |
||
==References== |
==References== |
||
{{ |
{{Reflist}} |
||
==External links== |
==External links== |
||
| Line 47: | Line 47: | ||
{{Radiopharmaceuticals}} |
{{Radiopharmaceuticals}} |
||
{{Uncategorized stub|date=September 2010}} |
|||
| ⚫ | |||
| ⚫ | |||
Revision as of 11:34, 28 September 2010
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | CD20 |
| Clinical data | |
| ATC code | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| Chemical and physical data | |
| Formula | C6416H9874N1688O1987S44 |
| Molar mass | 143859.7 g/mol g·mol−1 |
Tositumomab is a drug for the treatment of follicular lymphoma. It is a IgG2a anti-CD20 monoclonal antibody derived from immortalized mouse cells.
Tositumomab is applied in a sequential infusion followed by iodine (131I) tositumomab, which is the same antibody covalently bound to the radionuclide iodine-131 (131I).[1] 131I emits both beta and gamma radiation and decays with a half-life of 8 days.
Clinical trials have established the efficacy of the tositumomab/iodine (131I) tositumomab regimen in patients with relapsed or chemotherapy/rituxan refractory follicular lymphoma.
This drug combination is manufactured by Corixa (now GlaxoSmithKline). It sells in the U.S. under the trade name Bexxar.
There is some evidence that it may cause a smaller decrease in platelet counts than ibritumomab tiuxetan does.[2]
References
- ^ Bexxar Prescribing Information
- ^ Jacene HA, Filice R, Kasecamp W, Wahl RL (2007). "Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice". J. Nucl. Med. 48 (11): 1767–76. doi:10.2967/jnumed.107.043489. PMID 17942813.
{{cite journal}}: CS1 maint: multiple names: authors list (link)
External links
- Bexxar regimen entry in the public domain NCI Dictionary of Cancer Terms
 | This article has not been added to any content categories. Please help out by adding categories to it so that it can be listed with similar articles, in addition to a stub category. (September 2010) |
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |